Sugi Predict

Sugi Predict / Compounds / SCHEMBL377595

SCHEMBL377595

SCHEMBL377595

CC(=O)Oc1ccc(O)c([N+](=O)[O-])c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.51
▸ GPR35 Q9HC97 2/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ TP53 P04637 1/20 0.51
▸ HPGD P15428 1/20 0.51
▸ TSHR P16473 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ L3MBTL1 Q9Y468 2/20 0.50
▸ ALOX15 P16050 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ ALDH5A1 P51649 1/20 0.47
▸ ABAT P80404 1/20 0.47
▸ CA12 O43570 1/20 0.47
▸ CA1 P00915 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ MAPT P10636 5/20 0.46
▸ KDM4E B2RXH2 3/20 0.46
▸ LMNA P02545 3/20 0.46
▸ USP2 O75604 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7564089 0.87 GPR35 (0.49) MAPK1GPR35ALDH1A1TP53HPGD
SCHEMBL9635580 0.87 GPR35 (0.51) MAPK1GPR35ALDH1A1HPGDL3MBTL1
SCHEMBL823830 0.86 ALDH1A1 (0.50) MAPK1ALDH1A1HPGDTSHRMAPT
SCHEMBL18328833 0.84 MAPK1 (0.46) MAPK1GPR35ALDH1A1TP53HPGD
SCHEMBL29269278 0.83 MAPK1 (0.54) MAPK1GPR35ALDH1A1TP53HPGD
SCHEMBL7421553 0.83 TSHR (0.54) MAPK1ALDH1A1HPGDTSHRSMN1; SMN2
SCHEMBL2057240 0.83 SMN1; SMN2 (0.47) MAPK1GPR35ALDH1A1TP53HPGD
SCHEMBL228433 0.82 MAPT (0.55) MAPK1ALDH1A1HPGDMAPTKDM4E
SCHEMBL19071956 0.82 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2CA1MAPTKDM4E
SCHEMBL1865349 0.82 MAPT (0.61) MAPK1ALDH1A1HPGDMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025085675-A1 CONJUGATES, COMPOSITIONS AND METHODS FOR TREATING RSV INFECTION NIEDRAUER MARY LYNN (US) 2025-04-24 — — WO claimed
WO-2025085664-A1 CONJUGATES, COM POSITIONS AND METHODS FOR TREATING INFLUENZA NIEDRAUER MARY LYNN (US) 2025-04-24 — — WO claimed
US-8287764-B2 Coated particles AKZO NOBEL N.V. (NL) 2012-10-16 — — US claimed
US-20110133128-A1 COATED PARTICLES AKZO NOBEL N.V. (NL) 2011-06-09 — — US claimed
EP-2303961-A1 COATED PARTICLES Akzo Nobel N.V. (NL) 2011-04-06 — — EP claimed
WO-2010010052-A1 COATED PARTICLES AKZO NOBEL N.V. (NL) 2010-01-28 — — WO claimed
JP-6277046-A — — None — — JP disclosed
CN-122094942-A Novel azide condensation of 6-hydroxybenzomorpholine (3, 4-dihydro-2H-1, 4-benzoxazin-6-ol) — 2026-05-26 — — CN disclosed
WO-2026044019-A1 COMPOSITIONS AND METHODS FOR TREATING INFLUENZA INFECTION LOW STEWART (US) 2026-02-26 — — WO disclosed
WO-2025099125-A1 NEW TELESCOPING SYNTHESES OF 6-HYDROXY-BENZOMORPHOLINE (3,4-DIHYDRO-2H-1,4-BENZOXAZIN-6-OL) WELLA GERMANY GMBH (DE) 2025-05-15 — — WO disclosed
WO-2025085675-A1 CONJUGATES, COMPOSITIONS AND METHODS FOR TREATING RSV INFECTION NIEDRAUER MARY LYNN (US) 2025-04-24 — — WO disclosed
US-20230210808-A1 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS CYMABAY THERAPEUTICS, INC. 2023-07-06 — — US disclosed
US-20220387403-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY CVI PHARMACEUTICALS LIMITED (KY) 2022-12-08 — — US disclosed
US-5229510-A β-lactams useful in determining the amount of elastase in a clinical sample MERCK & CO., INC. (US) 1993-07-20 — — US disclosed
WO-1993011236-A1 PRODUCTION OF ANTI-SELF ANTIBODIES FROM ANTIBODY SEGMENT REPERTOIRES AND DISPLAYED ON PHAGE MEDICAL RESEARCH COUNCIL (GB) 1993-06-10 — — WO disclosed
EP-0483194-A1 IgG3 ANTIBODIES WITH SHORTENED HINGE REGION AND A COMPLEMENT ACTIVATION TEST. DYNAL AS (NO) 1992-05-06 — — EP disclosed
WO-1991001335-A1 IgG3 ANTIBODIES WITH SHORTENED HINGE REGION AND A COMPLEMENT ACTIVATION TEST DYNAL A.S. (NO) 1991-02-07 — — WO disclosed
WO-1991001368-A1 HAPTEN/ANTI-HAPTEN AFFINITY LINKING IN CELL SEPARATION DYNAL A.S. (NO) 1991-02-07 — — WO disclosed
EP-0411751-A1 Renin inhibitory peptides Beecham Group p.l.c. (GB) 1991-02-06 — — EP disclosed
US-4593106-A 4-[2-(dialkylamino)ethyl]-7-hydroxyisatins SMITHKLINE BECKMAN CORPORATION (US) 1986-06-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220387403-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY LIPC, FABP1, CPT1A MAPK1 2564/4885GPR35 867/4885ALDH1A1 299/4885
US-20230210808-A1 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS PPARA, PPARG, PPARD MAPK1 2873/4885GPR35 632/4885ALDH1A1 1562/4885
US-20110133128-A1 COATED PARTICLES CD63, CD44, S100A4 MAPK1 4340/4885GPR35 4437/4885ALDH1A1 2268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.